OIRA Conclusion of EO 12866 Regulatory Review
RIN: 0910-AG88 View EO 12866 Meetings | Received Date: 06/18/2013 |
Title: Revision of Postmarketing Reporting Requirements Discontinuance or Interruption in Supply of Certain Products (Drug Shortages) | |
Agency/Subagency: HHS / FDA | Stage: Proposed Rule |
Concluded Action: Consistent with Change | Concluded Date: 10/01/2013 |
Section 3(f)(1) Significant *: No | |
Legal Deadline: Statutory | Economically Significant **: Yes |
Publication Date: 11/04/2013 | Unfunded Mandates: No |
Major: Yes | Related To Homeland Security: No |
Regulatory Flexibility Analysis Required: Undetermined | Small Entities Affected: |
Federalism Implications: No | Affordable Care Act [Pub. L. 111-148 & 111-152]: No |
International Impacts: No | Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]: No |
Pandemic Response: Uncollected | |
|